IDEXX Laboratories Inc

IDEXX Laboratories Inc(IDXX)股票分析

$556.690

+1.726 (+0.31%)收盘时

Loading chart…
High
561.240
Open
547.680
VWAP
553.84
Vol
698.43K
Mkt Cap
40.79B
Low
543.600
Amount
386.82M
EV/EBITDA, TTM
24.67

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants.

www.idexx.com

AI analysis of IDEXX Laboratories Inc (IDXX)

hold

IDEXX Laboratories is currently a hold. The stock is priced at $554.99, which is below the lowest analyst target of $620 from UBS, indicating potential for upside. However, the RSI is at 49.226, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 37.45, which is relatively high, indicating that the stock may be overvalued at this price point. The main risk is the recent downgrade from Barclays, which lowered its price target from $800 to $710, reflecting cautious sentiment in the market.

Analyst Ratings (10)

+42.41% upside
Buy
6 Buy
3 Hold
1 Sell
Current: 556.69
最低
750.00
平均
792.78
最高
850.00

Barclays

2026-08-11

目标价

$710

Overweight

Citi

2026-08-05

目标价

$670

Neutral

UBS

2026-07-27

目标价

$620

Neutral

Stifel

2026-07-15

目标价

$564.42

Buy

BofA

2026-05-05

目标价

$660

Neutral

估值指标

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX) is 36.90, compared to its 5-year average forward P/E of 47.08.

Forward P/E

Undervalued
5Y Average P/E
47.08
Current P/E
36.90
高估
57.12
低估
37.03

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
32.78
Current EV/EBITDA
24.67
高估
39.51
低估
26.05

Forward P/S

Fair
5Y Average P/S
10.53
Current P/S
8.51
高估
12.55
低估
8.50

Alphio AI Price Scenarios for IDXX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IDXX

$650.45

情景价格

B

Base

Base · 50%IDXX

$608.98

情景价格

B

Bear

Bear · 25%IDXX

$597.63

情景价格

Whales holding IDXX

B

Bellevue Asset Management AG

+ HoldingIDXX

+11.29%

3M Return

T

Tremblant Capital Group

+ HoldingIDXX

+9.57%

3M Return

C

Chilton Investment Company, Inc.

+ HoldingIDXX

+9.07%

3M Return

V

Veritas Investment Management LLP

+ HoldingIDXX

+7.28%

3M Return

B

Bradley, Foster & Sargent, Inc.

+ HoldingIDXX

+6.86%

3M Return

L

Lazard Frères Gestion SAS

+ HoldingIDXX

+5.15%

3M Return

事件时间线

2026-08-11 (ET)

07:30:00

IDEXX Launches Catalyst proBNP Test, Enhancing Cardiac Testing Capabilities

2026-08-04 (ET)

09:00:00

IDEXX Laboratories Q2 Revenue $1.22B Beats Expectations

08:30:00

Idexx Reports Q2 EPS of $4.27, Beating Consensus of $3.93

07:00:00

IDEXX Laboratories Reports Q2 Revenue of $1.22B

07:00:00

2026 EPS Consensus at $14.66, Revenue View Adjusted to $4.70B-$4.745B

资讯

IDXX FAQ — answered by Alphio AI

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

IDEXX Laboratories is currently a hold. The stock is priced at $554.99, which is below the lowest analyst target of $620 from UBS, indicating potential for upside. However, the RSI is at 49.226, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 37.45, which is relatively high, indicating that the stock may be overvalued at this price point. The main risk is the recent downgrade from Barclays, which lowered its price target from $800 to $710, reflecting cautious sentiment in the market.

10 analysts cover IDXX: 6 rate it Buy, 3 Hold and 1 Sell. The average price target is 792.78.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始